Growth Hormone Perturbations in Fibromyalgia: A Review

Seminars in Arthritis and Rheumatism

Volumn 36, Issue 6, 2007, Pages 357-379

  Jones, Kim D ^a   Deodhar, Parimal ^a   Lorentzen, Ashley ^a   Bennett, Robert M ^a   Deodhar, Atul A ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

fibromyalgia; growth hormone (GH); growth hormone releasing hormone (GHRH); hypothalamus; insulin like growth factor 1 (IGF 1); pituitary; somatostatin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ARGININE; BROMOCRIPTINE; BUSPIRONE; CLONIDINE; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYPROHEPTADINE; DEXAMETHASONE; FATTY ACID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; INSULIN; LACTATE DEHYDROGENASE; LACTIC ACID; LEUCINE; LEVODOPA; PROLACTIN; PROTIRELIN; PYRIDOSTIGMINE; RECOMBINANT GROWTH HORMONE; SALBUTAMOL; SOMATOMEDIN C; SOMATOSTATIN; SUBSTANCE P; THYROTROPIN;

ARTHRALGIA; ARTICLE; CACHEXIA; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; FIBROMYALGIA; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INFLAMMATORY DISEASE; MYOFASCIAL PAIN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

FEMALE; FIBROMYALGIA; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN-LIKE GROWTH FACTOR I; MALE; RANDOMIZED CONTROLLED TRIALS;

EID: 34248651389     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.09.006     Document Type: Article

References (137)

1. Wolfe F., Ross K., Anderson J., Russell I.J., and Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 1 (1995) 19-28
2. Bennett R.M. Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 39 10 (1996) 1627-1634
3. Jones K.D., Burckhardt C.S., Clark S.R., Bennett R.M., and Potempa K.M. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol 29 5 (2002) 1041-1048
4. Wolfe F., Anderson J., Harkness D., Bennett R.M., Caro X.J., Goldenberg D.L., et al. Work and disability status of persons with fibromyalgia. J Rheumatol 24 6 (1997) 1171-1178
5. Thorson K. The fibromyalgia problem. J Rheumatol 25 5 (1998) 1023 ; author reply, 1028-30.
6. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 2 (1990) 160-172
7. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74 4 (1999) 385-398
8. Price D.D., and Staud R. Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl 75 (2005) 22-28
9. Staud R., and Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med 2 3 (2001) 208-215
10. Adler G.K., and Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin North Am 31 1 (2005) 187-202
11. Cohen H., Neumann L., Shore M., Amir M., Cassuto Y., and BuskilaD. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 29 4 (2000) 217-227
12. Martínez-Lavín M., Hermosillo A.G., Rosas M., and Soto M.E. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 41 11 (1998) 1966-1971
13. Neeck G., and Crofford L.J. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 26 4 (2000) 989-1002
14. Neeck G. Pathogenic mechanisms of fibromyalgia. Ageing Res Rev 1 2 (2002) 243-255
15. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med 67 2 (2005) 288-294
16. Boscarino J.A. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann NY Acad Sci 1032 (2004) 141-153
17. Cleare A.J. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 15 2 (2004) 55-59
18. Fries E., Hesse J., Hellhammer J., and Hellhammer D.H. A new view on hypocortisolism. Psychoneuroendocrinology 30 10 (2005) 1010-1016
19. Heim C., Ehlert U., and Hellhammer D.H. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 25 1 (2000) 1-35
20. Lutgendorf S.K., Kreder K.J., Rothrock N.E., Hoffman A., Kirschbaum C., Sternberg E.M., et al. Diurnal cortisol variations and symptoms in patients with interstitial cystitis. J Urol 167 3 (2002) 1338-1343
21. Bonaz B., and Rivest S. Effect of a chronic stress on CRF neuronal activity and expression of its type 1 receptor in the rat brain. Am J Physiol 275 (1998) R1438-R1449
22. Van Cauter E., Plat L., and Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 21 6 (1998) 553-566
23. Casanueva F.F., Villanueva L., Cabranes J.A., Cabezas-Cerrato J., and Fernandez-Cruz A. Cholinergic mediation of growth hormone secretion elicited by arginine, clonidine, and physical exercise in man. J Clin Endocrinol Metab 59 3 (1984) 526-530
24. Vigas M., Malatinsky J., Nemeth S., and Jurcovicova J. Alpha-adrenergic control of growth hormone release during surgical stress in man. Metabolism 26 4 (1977) 399-402
25. Cornil A., Glinoer D., Leclerco R., and Copinschi G. Adrenocortical and somatotrophic secretions in acute and chronic respiratory insufficiency. Am Rev Respir Dis 112 1 (1975) 77-81
26. Sachar E.J., Mushrush G., Perlow M., Weitzman E.D., and Sassin J. Growth hormone responses to L-dopa in depressed patients. Science 178 67 (1972) 1304-1305
27. Alba-Roth J., Müller O.A., Schopohl J., and von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab 67 6 (1988) 1186-1189
28. Cahill Jr. G.F., Herrera M.G., Morgan A.P., Soeldner J.S., Steinke J., Levy P.L., et al. Hormone-fuel interrelationships during fasting. J Clin Invest 45 11 (1966) 1751-1769
29. Ho K.Y., Veldhuis J.D., Johnson M.L., Furlanetto R., Evans W.S., Alberti K.G., et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 81 4 (1988) 968-975
30. Miller K.K., Biller B.M., Lipman J.G., Bradwin G., Rifai N., and Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab 90 2 (2005) 768-774
31. Vance M.L., and Mauras N. Growth hormone therapy in adults and children. N Engl J Med 14 (1999) 1206-1216 341(16)
32. Money J., and Wolff G. Late puberty, retarded growth, and reversible hyposomatotropism (psychosocial dwarfism). Adolescence 9 (1974) 121-134
33. Money J. The syndrome of abuse dwarfism (psychosocial dwarfism or reversible hyposomatotropism). Am J Dis Child 131 (1977) 508-513
34. Merriam G.R., Carney C., Smith L.C., and Kletke M. Adult growth hormone deficiency: current trends in diagnosis and dosing. J Pediatr Endocrinol Metab 17 4 (2004) 1307-1320
35. Simon D., Lucidarme N., Prieur A.M., Ruiz J.C., and Czernichow P. Linear growth in children suffering from juvenile idiopathic arthritis requiring steroid therapy: natural history and effects of growth hormone treatment on linear growth. J Pediatr Endocrinol Metab 14 Suppl 6 (2001) 1483-1486
36. Wehrenberg W.B., Janowski B.A., Piering A.W., Culler F., and Jones K.L. Glucocorticoids: potent inhibitors and stimulators of growth hormone secretion. Endocrinology 1266 (1990) 3200-3203
37. Devesa J., Barros M.G., Gondar M., Tresguerres J.A., and Arce V. Regulation of hypothalamic somatostatin by glucocorticoids. J Steroid Biochem Mol Biol 53 1 (1995) 277-282
38. Webb S.M., Andres-Aguayo I., Rojas-Garcia R., Ortega E., Gallardo E., MestronA, et al. Neuromuscular dysfunction in adult growth hormone deficiency. Clin Endocrinol (Oxf) 59 4 (2003) 450-458
39. Wuster C., Harle U., Rehn U., Müller C., Knauf K., Koppler D., et al. Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis. Growth Horm IGF Res 8 (1998) 87-94
40. Svensson J., Tivesten A., and Isgaard J. Growth hormone and the cardiovascular function. Minerva Endocrinol 30 1 (2005) 1-13
41. Geusens P.P., and Boonen S. Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 58 Suppl 3 (2002) 49-55
42. Jorgensen J.O., Müller J., Möller J., Wolthers T., Vahl N., Juul A., et al. Adult growth hormone deficiency. Horm Res 42 (1994) 235-241
43. Mahajan T., Crown A., Checkley S., Farmer A., and Lightman S. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol 151 3 (2004) 325-332 325-32
44. Golgeli A., Tanriverdi F., Suer C., Gokce C., Ozesmi C., Bayram F., et al. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy. Eur J Endocrinol 150 2 (2004) 153-159
45. Van Cauter E., Latta F., Nedeltcheva A., Spiegel K., Leproult R., Vandenbril C., et al. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res 14 Suppl A (2004) S10-S17
46. Van Cauter E., Plat L., and Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 21 6 (1998) 553-566
47. Cuneo R.C., Judd S., Wallace J.D., Perry-Keene D., Burger H., Lim-Tio S., et al. The Australian Multicenter Trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 83 1 (1998) 107-116
48. Alanoglu E., Ulas U.H., Özdag F., Odabasi Z., Çakçi A., and Vural O. Auditory event-related brain potentials in fibromyalgia syndrome. Rheumatol Int 25 5 (2005) 345-349
49. Gola M., Bonadonna S., Doga M., and Giustina A. Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 90 3 (2005) 1864-1870
50. Johannsson G., and Bengtsson B.A. Growth hormone and the metabolic syndrome. J Endocrinol Invest 22 Suppl 5 (1999) 41-46
51. Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol 151 1 (2004) S23-S27
52. Laron Z. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity?. Mech Ageing Dev 126 2 (2005) 305-307
53. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Shalet S.M., Vance M.L., et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91 5 (2006) 1621-1634
54. Bercu B.B., Shulman D., Root A.W., and Spiliotis B.E. Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 63 3 (1986) 709-716
55. Lunt H., Tucker A.J., Bullen H., Gibbs C., and Wilkin T.J. Overnight urinary growth hormone measurement in the diagnosis of acromegaly. Clin Endocrinol (Oxf) 33 2 (1990) 205-212
56. Carroll P.V., Christ E.R., Bengtsson B.A., Carlsson L., Christiansen J.S., Clemmons D., et al. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83 2 (1998) 379-381
57. Biller B.M., Samuels M.H., Zagar A., Cook D.M., Arafah B.M., Bonert V., et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87 5 (2002) 2067-2079
58. Evans A.J. Screening tests for growth hormone deficiency. J R Soc Med 88 3 (1995) 161P-165P
59. Fisker S., Jorgensen J.O., Orskov H., and Christiansen J.S. L-arginine and insulin-tolerance tests in the diagnosis of adult growth hormone deficiency: influence of confounding factors. Clin Endocrinol (Oxf) 48 1 (1998) 109-115
60. Hoeck H.C., Vestergaard P., Jakobsen P.E., Falhof J., and Laurberg P. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues. J Clin Endocrinol Metab 85 4 (2000) 1467-1472
61. Ghigo E., Imperiale E., Boffano G.M., Mazza E., Bellone J., Arvat E., et al. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone. J Endocrinol Invest 13 4 (1990) 307-316
62. Procopio M., Maccario M., Savio P., Valetto M.R., Aimaretti G., Grottoli S., et al. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. Panminerva Med 40 1 (1998) 13-17
63. Florini J.R., Prinz P.N., Vitiello M.V., and Hintz R.L. Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 40 1 (1985) 2-7
64. Granada M.L., Murillo J., Lucas A., Salinas I., Llopis M.A., Castells I., et al. Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinol 142 3 (2000) 243-253
65. Aimaretti G., Corneli G., Razzore P., Bellone S., Baffoni C., Bellone J., et al. Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults. J Endocrinol Invest 21 8 (1998) 506-511
66. Genetically engineered human growth hormone approved. FDA Drug Bull 15 4 (1985) 38-39
67. James J.S. FDA approves human growth hormone for wasting syndrome. AIDS Patient Care STDS 10 6 (1996) 379-380
68. Rapaport R. Adult height predictions for Constitutional Growth Delay, growth hormone treatment for idiopathic short stature and the FDA: are they related?. Horm Res 65 4 (2006) 197-199
69. Bollerslev J., Hallen J., Fougner K.J., Jorgensen A.P., Kristo C., Fagertun H., et al. Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. Eur J Endocrinol 153 3 (2005) 379-387
70. Giusti M., Meineri I., Malagamba D., Cuttica C.M., Fattacciu G., Menichini U., et al. Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. Eur J Clin Invest 28 1 (1998) 13-19
71. Hoffman A.R., Kuntze J.E., Baptista J., Baum H.B., Baumann G.P., Biller B.M., et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89 5 (2004) 2048-2056
72. Mukherjee A., Murray R.D., and Shalet S.M. Impact of growth hormone status on body composition and the skeleton. Horm Res 62 3 (2004) 35-41
73. Murray R.D., Skillicorn C.J., Howell S.J., Lissett C.A., Rahim A., Smethurst L.E., and e.a. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 51 5 (1999) 565-573
74. Cook D.M., Ludlam W.H., and Cook M.B. The adult growth hormone deficiency syndrome. Adv Intern Med 45 (2000) 297-5
75. Giordano R., Lanfranco F., Bo M., Pellegrino M., Picu A., Baldi M., et al. Somatopause reflects age-related changes in the neural control of GH/IGF-I axis. J Endocrinol Invest 28 3 (2005) 94-98
76. Toogood A.A., O'Neill P.A., and Shalet S.M. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 81 (1996) 460-465
77. Shalet S.M. GH deficiency in the elderly: the case for GH replacement. Clin Endocrinol (Oxf) 53 3 (2000) 279-280
78. Savine R., and Sonksen P.H. Is the somatopause an indication for growth hormone replacement?. J Endocrinol Invest 22 Suppl 5 (1999) 142-149
79. Fernholm R., Bramnert M., Hagg E., Hilding A., Baylink D.J., Mohan S., et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85 11 (2000) 4104-4112
80. Nam S.Y., Kim K.R., Cha B.S., Song Y.D., Lim S.K., Lee H.C., et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 25 8 (2001) 1101-1107
81. Tanaka T., Seino Y., Fujieda K., Igarashi Y., Yokoya S., Tachibana K., et al. Pharmacokinetics and metabolic effects of high-dose growth hormone administration in healthy adult men. Endocr J 46 4 (1999) 605-612
82. Wallymahmed M.E., Foy P., Shaw D., Hutcheon R., Edwards R.H., and MacFarlane I.A. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf) 47 4 (1997) 439-446
83. Ur E., Serri O., Legg K., Murphy L.J., and Ezzat S. Canadian guidelines for the management of adult growth hormone deficiency. Clin Invest Med 29 2 (2006) 83-90
84. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 2 (1999) 151-156
85. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90 12 (1998) 911-915
86. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 9113 (1998) 1393-1396
87. Fischer F., Schulte H., Mohan S., Tataru M.C., Kohler E., Assmann G., et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 61 5 (2004) 595-602
88. Katic M., and Kahn C.R. The role of insulin and IGF-1 signaling in longevity. Cell Mol Life Sci 62 3 (2005) 320-343
89. Murphy C.T., McCarroll S.A., Bargmann C.I., Fraser A., Kamath R.S., Ahringer J., et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424 6946 (2003) 277-283
90. Christ E.R., Cummings M.H., Lumb P.J., Crook M.A., Sonksen P.H., and Russell-Jones D.L. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin Endocrinol (Oxf) 51 2 (1999) 173-179
91. Toogood A.A. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm Res 60 Suppl 1 (2003) 105-111
92. How to read clinical journals: V: to distinguish useful from useless or even harmful therapy. Can Med Assoc J 124 9 (1981) 1156-1162
93. Squires B.P. Biomedical manuscripts: what editors want from authors and peer reviewers. Canadian Medical Association Journal 141 1 (1989) 17-19
94. Bennett R.M., Clark S.R., Campbell S.M., and Burckhardt C.S. Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis Rheum 35 10 (1992) 1113-1116
95. Bennett R.M., Cook D.M., Clark S.R., Burckhardt C.S., and Campbell S.M. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24 7 (1997) 1384-1389
96. Dinser R., Halama T., and Hoffmann A. Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol 27 10 (2000) 2482-2488
97. Ferraccioli G., Guerra P., Rizzi V., Baraldo M., Salaffi F., Furlanut M., et al. Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol 21 7 (1994) 1332-1334
98. Riedel W., Layka H., and Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 57 Suppl 2 (1998) 81-87
99. Romano T.J. Controlled study on serum insulin-like growth factor I and urinary excretion of growth hormone in fibromyalgia. J Rheumatol 23 1 (1996) 194
100. Bagge E., Bengtsson B., CarlssonL, and Carlsson J. Low growth hormone secretion in patients with fibromyalgia-a preliminary report on 10 patients and 10 controls. J Rheumatol 25 1 (1998) 145-148
101. Buchwald D., Umali J., and Stene M. Insulin-like growth factor-I (somatomedin C) levels in chronic fatigue syndrome and fibromyalgia. J Rheumatol 23 4 (1996) 739-742
102. Denko C.W., and Malemud C.J. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum 35 1 (2005) 24-34
103. Dessein P.H., Shipton E.A., Joffe B.I., Hadebe D.P., Stanwix A.E., and Van der Merwe B.A. Hyposecretion of adrenal androgens and the relation of serum adrenal steroids, serotonin and insulin-like growth factor-1 to clinical features in women with fibromyalgia. Pain 83 2 (1999) 313-319
104. Gürsel Y., Ergin S., Ulus Y., Erdogan M.F., Yalçin P., and Evcik D. Hormonal responses to exercise stress test in patients with fibromyalgia syndrome. Clin Rheumatol 20 6 (2001) 401-405
105. Landis C.A., Lentz M.J., Rothermel J., Riffle S.C., Chapman D., Buchwald D., et al. Decreased nocturnal levels of prolactin and growth hormone in women with fibromyalgia. J Clin Endocrinol Metab 86 4 (2001) 1672 -
106. Leal-Cerro A., Povedano J., Astorga R., Gonzalez M., Silva H., Garcia-Pesquera F., et al. The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 84 9 (1999) 3378-3381
107. Denko C.W., and Malemud C.J. Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int 25 2 (2005) 146-151
108. Meiworm L., Deodar A., and Bennett R. Pyridostigmine induced enhancement of growth hormone release in fibromyalgia patients. Arthritis Rheum 39 (1996) S276
109. Jones K.D., Burckhardt C.S., Deodhar A.A., Perrin N.A., Hanson G., and Bennett R.M. Pyridostigmine normalizes growth hormone response to acute exercise in fibromyalgia patients, but is not superior to exercise for symptom control. Arthritis Rheum 52 9 (2005) S267
110. Paiva E.S., Deodhar A., Jones K.D., and Bennett R. Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 46 5 (2002) 1344-1350
111. Griep E.N., Boersma J.W., and de Kloet E.R. Pituitary release of growth hormone and prolactin in the primary fibromyalgia syndrome. J Rheumatol 21 11 (1994) 2125-2130
112. Bennett R.M., Clark S.C., and Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104 3 (1998) 227-231
113. Valkeinen H., Häkkinen K., Pakarinen A., Hannonen P., Häkkinen A., Airaksinen O., et al. Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scand J Rheumatol 34 4 (2005) 309-314
114. Bennett R. Growth hormone in musculoskeletal pain States. Curr Pain Headache Rep 9 5 (2005) 331-338
115. Bennett R.M. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 4 4 (2002) 306-312
116. Crofford L.J., Young E.A., Engleberg N.C., Korszun A., Brucksch C.B., McClure L.A., et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 18 4 (2004) 314-325
117. Naveri H., Kuoppasalmi K., and Harkonen M. Plasma glucagon and catecholamines during exhaustive short-term exercise. Eur J Appl Physiol Occup Physiol 53 4 (1985) 308-311
118. Eason M.G., Francis R.S., and Kuhn C.M. mu-Opioid agonists stimulate growth hormone secretion in immature rats. Neuroendocrinology 63 6 (1996) 489-497
119. Wehrenberg W.B., Bloch B., and Ling N. Pituitary secretion of growth hormone in response to opioid peptides and opiates is mediated through growth hormone-releasing factor. Neuroendocrinology 41 1 (1985) 13-16
120. Arvat E., Giordano, and R. Grottoli S, Ghigo E. Benzodiazepines and anterior pituitary function. J Endocrinol Invest 25 8 (2002) 735-747
121. Widerlov E., Wide L., and Sjostrom R. Effects of tricyclic antidepressants on human plasma levels of TSH, GH and prolactin. Acta Psychiatr Scand 58 5 (1978) 449-456
122. Raap D.K., and Van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65 12 (1999) 1217-1235
123. Lebenthal Y., and Weintrob N. Growth hormone: missing link between selective serotonin uptake inhibitors and reduced risk of colorectal cancer?. Lancet Oncol 7 6 (2006) 449-450 jun;
124. McCall-Hosenfeld J.S., Goldenberg D.L., Hurwitz S., and Adler G.K. Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 30 4 (2003) 809-814
125. Martínez-Lavín M. Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep 8 5 (2004) 385-389
126. Furlan R., Colombo S., Perego F., Atzeni F., Diana A., Barbic F., et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 32 9 (2005) 1787-1793
127. Bennett R. Fibromyalgia: present to future. Curr Rheumatol Rep 7 5 (2005) 371-376
128. Shah J.P., Phillips T.M., and DanoffJVGerber L.H. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 99 l5 (2005) 1977-1984
129. Staud R. Are tender point injections beneficial: the role of tonic nociception in fibromyalgia. Curr Pharm Des 12 1 (2006) 23-27
130. Müller E.E., Locatelli V., and Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 79 2 (1999) 511-607
131. McCain G.A., and Tilbe K.S. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl 19 (1989) 154-157
132. Eisinger J., Plantamura A., and Ayavou T. Glycolysis abnormalities in fibromyalgia. J Am Coll Nutr 13 2 (1994) 144-148
133. Jacobsen S., Main K., Danneskiold-Samsøe B., and Skakkebaek N.E. A controlled study on serum insulin-like growth factor-I and urinary excretion of growth hormone in fibromyalgia. J Rheumatol 22 6 (1995) 1138-1140
134. Buchwald D., Umali J., and Stene M. Insulin-like growth factor-I (somatomedin C) levels in chronic fatigue syndrome and fibromyalgia. J Rheumatol 23 4 (1996) 739-742
135. Riedel W., Schlapp U., Leck S., Netter P., and Neeck G. Blunted ACTH and cortisol responses to systemic injection of corticotropin-releasing hormone (CRH) in fibromyalgia: role of somatostatin and CRH-binding protein. Ann NY Acad Sci 966 (2002) 483-490
136. Häkkinen K., Pakarinen A., Hannonen P., Häkkinen A., Airaksinen O., Valkeinen H., et al. Effects of strength training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones in premenopausal women with fibromyalgia. J Rheumatol 29 6 (2002) 1287-1295
137. Malt E.A., Olafsson S., Aakvaag A., Lund A., and Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 75 1 (2003) 77-82